EPISODE · May 29, 2026 · 5 MIN
What’s on the horizon for relapsed/refractory MM in 2026?
from Multiple Myeloma Hub
The Multiple Myeloma Hub spoke with Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. We asked, What’s on the horizon for the treatment of relapsed/refractory multiple myeloma (MM) in 2026? In this interview, Lonial provides an overview of recent and emerging developments in relapsed/refractory MM, highlighting advances in immune-based therapies and their potential to improve outcomes in the early relapsed setting. He also discusses how these approaches may influence treatment decision-making, the movement of novel therapies into earlier lines of treatment, and the broader implications for future disease management. Hosted on Acast. See acast.com/privacy for more information.
What this episode covers
The Multiple Myeloma Hub spoke with Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. We asked, What’s on the horizon for the treatment of relapsed/refractory multiple myeloma (MM) in 2026? In this interview, Lonial provides an overview of recent and emerging developments in relapsed/refractory MM, highlighting advances in immune-based therapies and their potential to improve outcomes in the early relapsed setting. He also discusses how these approaches may influence treatment decision-making, the movement of novel therapies into earlier lines of treatment, and the broader implications for future disease management. Hosted on Acast. See acast.com/privacy for more information.
NOW PLAYING
What’s on the horizon for relapsed/refractory MM in 2026?
No transcript for this episode yet
Similar Episodes
Apr 6, 2026 ·25m
Mar 30, 2026 ·27m